Description

Insulet Corporation’s 10th Straight Year Above 20% Revenue Growth Raises Expectations

Insulet Corporation’s latest earnings results reflect both positive growth trends and potential areas for investor consideration. The company concluded 2025 with solid financial performance, marked by Insulet’s 10th consecutive year of over 20% revenue growth on a constant currency basis. This achievement demonstrates the strength of Insulet’s business model and the broad acceptance of its Omnipod insulin delivery system. The company’s overall revenue for the year exceeded $2.7 billion, with a 30% growth rate, underpinned by substantial expansion in both U.S. and international markets. U.S. revenues witnessed a 27% increase, while international operations grew by 39% on a constant currency basis. This reflects strong adoption of the Omnipod technology, which continues to attract new customer starts, particularly among individuals transitioning from multiple daily injections. Key areas of growth for Insulet include the U.S.